INTRODUCTION
============

The persistent beneficial effects of breast milk ingested in the neonatal intensive care unit (NICU) on growth and developmental outcome and its anti-infectious properties have been reported in extremely low birth weight infants (ELBWIs) whose birth weight is less than 1000 gm.[@B1][@B2][@B3] Therefore, breast milk has been considered to be the ideal food, and continued efforts have been made to feed breast milk to all ELBWIs in the NICU.[@B4] However, ELBWIs are at the highest risk of developing severe symptomatic postnatal cytomegalovirus (CMV) infection manifesting as sepsis-like symptoms or pneumonitis.[@B5][@B6][@B7] Transmission of CMV through breast milk to ELBWIs has been known to be the primary source of postnatal CMV infection.[@B8] The majority of CMV immunoglobulin (Ig) G seropositive women becomes locally reactivated during lactation, and subsequently excretes CMV in the breast milk without clinical or laboratory signs of systemic infection.[@B2][@B7][@B8] Therefore, the risk of postnatal CMV infection might be even greater in ELBWIs born in the country or ethnicity with the high prevalence of CMV IgG seropositive women.[@B9]

The efficacy of various methods of CMV inactivation in breast milk, such as freeze-thawing or pasteurization, has not yet been elucidated. Although conventional pasteurization has been known to be effective in limiting CMV transmission through breast milk,[@B10][@B11][@B12] such manipulation might severely affect milk quality, thus limiting its benefits.[@B12][@B13] Freezing breast milk at -20℃ for several days has been found to reduce or destroy viral infectivity *in vitro*.[@B12][@B14] Moreover, the nutritional and immunological advantages of breast milk could be preserved with this method.[@B15] In a previous study, however, a certain level of infectivity has been shown to remain, and freeze-thawed breast milk could not completely prevent postnatal CMV infection.[@B14] Therefore, the available data regarding the efficacy of strategies such as freeze-thawing or pasteurization of breast milk in preventing postnatal CMV infection remain largely undetermined, and further studies are needed. In the present retrospective study, we evaluated the efficacy of freeze-thawing and pasteurization in preventing postnatal CMV infection transmitted through breast milk. The symptoms and outcome were described, once infected with CMV, to determine whether postnatal CMV infection acquired through breast milk leads to severe symptoms in ELBWIs.

MATERIALS AND METHODS
=====================

Data collection was approved by the Institutional Review Board of Samsung Medical Center, and the Institutional Review Board allowed a waiver of informed consent requirements for this retrospective chart review. Medical records of 385 out of 579 ELBWIs admitted to the NICU of Samsung Medical Center in the periods from January 1, 2007 to December 31, 2012 (period I, n=323) and from January 1, 2013 to September 30, 2013 (period II, n=62) were reviewed retrospectively. The details of 194 infants excluded in the analysis are shown in [Fig. 1](#F1){ref-type="fig"}. The study period was arbitrarily divided according to the methods of CMV inactivation in the stored human milk. During period I, each infant was fed with freeze-thawed mother\'s own breast milk that had been stored at -20℃ for more than 3 days. After an initial data analysis during period I showing that freeze-thawing reduced but did not completely prevent CMV transmission via breast milk,[@B16] our policy was changed to test whether pasteurization could eliminate the acquisition of postnatal CMV infection through breast milk, and, therefore, the infants were fed mother\'s own breast milk that had been conventionally pasteurized at 63℃ for 30 min during period II.[@B12] We also evaluated whether infants fed pasteurized milk might have an increased risk of several neonatal outcomes by comparing the outcomes with period I because pasteurization may reduce the immunological and clinical benefits of breast milk. Supplemental cow\'s whole milk for preterm infants (Premie®, Maeil Dairy Co. Ltd., Seoul, Korea) feeding was provided if necessary during the entire study period. Contact isolation guidelines were strictly implemented, and leukocyte depleted and irradiated blood was transfused to prevent acquired CMV infection throughout the whole study period.

Due to the high prevalence of CMV IgG positive mothers in Korea,[@B9] we developed a policy to routinely screen ELBWIs for CMV infection during admission to the NICU in 2007. Congenital CMV infection was ruled out by initial negative CMV screening test with urine CMV DNA polymerase chain reaction (PCR) performed within the first 2 postnatal weeks,[@B17] and the screening test was repeated if the patient was clinically suspicious of CMV infection, or every 2 to 6 weeks until discharge in order to detect postnatal CMV infection. The lowest limit of detection was 360 copies/mL. Postnatally acquired CMV infection was defined as an initial negative and subsequent positive on follow up CMV screening tests. Maternal CMV IgG level was checked only during period II.

The incidence of postnatally acquired CMV infection was assessed throughout the study period. Clinical findings including gestational age (GA), birth weight, Apgar score at 1 and 5 min, gender, small for GA, mode of delivery, premature rupture of membrane (PROM), pregnancy induced hypertension, maternal diabetes mellitus, and antenatal steroid use were analyzed. GA was determined by maternal last menstrual period and modified Ballard test. Small for gestational age was defined when the birth weight was less than the tenth percentile. Respiratory distress syndrome was defined by the requirement of surfactant and ventilator treatment. PROM was positive when the duration of PROM was more than 24 hours. To identify risk factors for the development of postnatally acquired CMV infection, the number and frequency of transfusion during admission and the percentage of breast milk feeding out of total oral intake during the first 8 postnatal weeks were calculated.

Outcome measures including death before discharge, bronchopulmonary dysplasia (BPD) (≥moderate),[@B18] intraventricular hemorrhage (IVH) (≥grade 3),[@B19] periventricular leukomalacia (PVL), necrotizing enterocolitis (≥Bell\'s stage IIb)[@B20] and retinopathy of prematurity (ROP)[@B21] requiring laser treatment were analyzed in each group. Duration of ventilator care, continuous positive airway pressure, and oxygen therapy were also reviewed respectively.

In the CMV group, clinical and laboratory abnormalities including respiratory deterioration, liver function, and hematologic abnormalities during the 3 weeks after first detection of viruria were assessed. Thrombocytopenia and neutropenia were defined as platelet level \<100000/mm^3^ and absolute neutrophil counts \<1000/mm^3^, respectively. Respiratory deterioration was defined as increased oxygen requirement with an increase in the inspired oxygen fraction ≥0.2 and/or increased mean airway pressure of ≥3 cmH~2~O. Retinitis and CMV encephalopathy were screened by an ophthalmologist and radiologist, respectively. Symptomatic CMV infection was defined only if other attributable causes that might cause these abnormalities were ruled out.

On follow-up at the corrected age (CA) of 2 years, developmental status such as cerebral palsy, hearing impairment, blindness and Bayley score, growth status, and catch-up growth were assessed.[@B22] Cerebral palsy was defined as a non-progressive central nervous system disorder characterized by abnormal muscle tone in at least one extremity and abnormal control of movement and posture.[@B23] Three groups were defined according to the severity of handicap as follows: group 1, children who could walk independently; group 2, children who could not walk but could sit independently; and group 3, children who could not sit independently (unable to maintain head and trunk control).[@B24] Hearing loss was defined as bilateral impairment requiring hearing aids, and blindness was defined as \<20/200 visual acuity. The mental development index and psychomotor development index according to Bayley Scales of Infants Development II,[@B22] assessed at a CA of 24 months, were also recorded. Catch-up growth was defined as achievement of normal (10-90th percentile) height, weight, and head circumference at CA of 2 years.

Statistical analyses
--------------------

Data are expressed as mean±standard deviation. Comparisons between categorical variables were performed using the chi square test or Fisher\'s exact test, and comparisons between continuous variables were evaluated using the Mann-Whitney U test. Logistic regression analysis was performed to compare risk factors and morbidities of postnatal CMV infection. A *p*-value of \<0.05 was considered statistically significant. The SPSS version 17 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses.

RESULTS
=======

Incidence of postnatal CMV infection
------------------------------------

During period I, while none (0/22) developed postnatal CMV infection with whole milk feeding, postnatal CMV infection was diagnosed in 8% (27/301) of ELBWIs fed with freeze-thawed breast milk ([Table 1](#T1){ref-type="table"}). The incidence of CMV infection rose significantly from 4% (3/70) to 10% (24/231) when fed with ≤60% or \>60%, respectively, of freeze-thawed mother\'s own breast milk out of the total oral intake during the first 8 postnatal weeks. The first detection of CMV PCR DNA in urine occurred at 54±24 postnatal days. CMV was also detected in 11/17 (65%) of the CMV infected ELBWIs\' stored breast milk at the first detection of viruria. However, during period II, although the maternal CMV IgG level was positive in 95% (59/62) of cases, none (0/62) developed postnatal CMV infection regardless of whole or breast milk feeding.

Clinical characteristics
------------------------

Demographic and clinical findings of the study groups during period I and II are shown in [Table 2](#T2){ref-type="table"}. During period I, GA was significantly lower in the postnatal CMV infection group than the control group. During period II, birth weight and Apgar score at 1 and 5 min were significantly lower compared to the control group in period I. Other variables including number and frequency of blood transfusion were not significantly different between the study groups.

Symptoms and signs of perinatal CMV infection
---------------------------------------------

In the present study, 82% (22/27) of the CMV infection group were symptomatic within 3 weeks after the first detection of viruria. Thrombocytopenia (63%, 17/27) was the most common abnormality, followed by neutropenia (44%, 12/27), direct hyperbilirubinemia of \>2 mg/dL (30%, 8/27), increased liver enzymes (26%, 7/27), and increased respiratory support (19%, 5/27). Neither retinitis nor encephalopathy was detected.

Adverse outcomes
----------------

Adverse outcomes of the study groups during period I and II are shown in [Table 3](#T3){ref-type="table"}. During period I, the incidence of BPD (≥moderate) and duration of ventilator care were significantly higher in the CMV group than the control group. During period II, duration of oxygen was significantly lower than period I. Other adverse outcomes such as ROP requiring surgery, NEC (≥stage II), IVH (≥grade III), and cystic PVL were not significantly different between the study groups.

Outcome at corrected age of 24 months
-------------------------------------

Neurodevelopmental outcome and growth status at the CA of 2 years in the postnatal CMV infection and control group infants during period I are shown in [Table 4](#T4){ref-type="table"}. Neurodevelopmental outcome and growth status were not significantly different between the study groups, and neither hearing loss nor blindness was reported in the CMV group.

Adjusted odds ratios for risk factors and adverse outcomes of CMV infection
---------------------------------------------------------------------------

In multiple logistic regression analysis, lower GA per week and breast milk feeding \>60% during the first 8 postnatal weeks were two independent risk factors for acquiring postnatal CMV infection ([Table 5](#T5){ref-type="table"}).

For adverse outcomes, development of BPD (≥moderate) was the only adverse outcome significantly associated with postnatal CMV infection ([Table 6](#T6){ref-type="table"}).

DISCUSSION
==========

The finding that CMV infection occurred only with breast milk but not with whole milk feeding supports the findings of previous studies showing that breast milk is the major route of postnatal CMV transmission, especially in ELBWIs.[@B5][@B25][@B26][@B27][@B28] However, as breast milk has been considered the ideal food for preterm newborns because of its nutritional benefits and anti-infectious components,[@B1][@B2][@B3] withholding breast milk and routine use of whole milk feeding, especially in the ELBWIs, is not acceptable in clinical practice. The majority of CMV IgG seropositive mothers reactivate CMV during lactation, and shed the virus into the breast milk.[@B12][@B29] In the present study, CMV DNA was detected in 70% stored breast milk at the first detection of viruria. As the transmission of CMV through breast milk has been observed only when an infant is fed CMV IgG positive breast milk with viral shedding,[@B25] the postnatal acquisition of CMV infection via breast milk could be prevented by simply avoiding the feeding of CMV seropositive breast milk. However, the CMV seropositive prevalence during period I was not routinely screened and thus unavailable. Therefore, considering the very high 95% CMV seropositive prevalence observed during period II in the present study, it would be virtually impossible to screen for and provide noninfectious CMV IgG negative breast milk to prevent CMV infection through breast milk in the clinical setting. Consequently, the development of other effective measures that could prevent CMV transmission through breast milk, especially in ELBWIs is an urgent issue.

In the present study, a positive correlation was observed between the acquisition of postnatal CMV infection and the amount of freeze-thawed breast milk ingested. A significantly higher (10%) incidence of postnatal CMV infection was observed when fed \>60% freeze-thawed breast milk out of the total oral intake compared with a 4% when fed ≤60% breast milk out of the total oral intake during the first 8 postnatal weeks. Furthermore, \>60% freeze-thawed breast milk feeding out of the total oral intake during the first 8 weeks was the independent risk factor for postnatal acquisition of CMV infection. These findings suggest that increased cumulative viral load in freeze-thawed breast milk plays a critical role in the acquisition of postnatal CMV infection via breast milk.[@B30]

Lower GA in preterm infants has been known to be an independent risk factor for the acquisition of postnatal CMV infection[@B5][@B8] probably due to a reduced trans-placental transfer of antibodies before GA of 28 weeks.[@B31] In the present study, the average GA of 24 weeks in the CMV infected ELBWIs was significantly lower compared to the 26 weeks of the control group. Furthermore, in addition to breast feeding \>60% of the total oral intake, the risk of postnatal CMV infection increased significantly with each week of decreasing GA. We assume that the absence of prenatally acquired anti-CMV antibodies during early GA in combination with the presence of CMV in breast milk is the most plausible explanation for the increased risk of postnatal acquisition of CMV infection via breast milk among ELBWIs with lower GA.[@B32]

Previous reports have shown that extremely immature infants are at the greatest risk for developing serious symptoms and sequelae following postnatal acquisition of CMV through the ingestion of breast milk.[@B2][@B6][@B8][@B25][@B33][@B34][@B35] In the present study, the rate of symptomatic CMV infection was higher than previous studies[@B2][@B8][@B33][@B36] because the enrolled infants were with much lower GA and birth weight compared with previous study, and the majority of CMV infected ELBWIs developed serious symptoms of CMV infection such as thrombocytopenia, neutropenia, hepatopathy, and respiratory deterioration. Moreover, symptomatic CMV infection was associated with significantly increased incidence of ≥moderate BPD. In concordance with our data showing that the majority of CMV infected more immature ELBWIs developed serious symptoms, Mehler, et al.[@B37] reported that all cases of CMV infected infants at 22-24 weeks\' gestation presented with thrombocytopenia, and 55% developed sepsis-like symptoms and signs of respiratory failure. Overall, these findings suggest that our data of high percentage of symptomatic CMV infection might be attributable to the lower GA, i.e., more immaturity even within ELBWIs. Yeager, et al.[@B38] reported that fatal or serious symptoms of transfusion acquired CMV infection were observed only in preterm infants born to seronegative mothers. Therefore, one possible explanation for this positive correlation of lower GA with the development of symptomatic CMV infection and sequelae in ELBWIs born even to seropositive mothers might be attributable to the lack of prenatal trans-placental transfer of anti-CMV IgG during early GA in ELBWIs.[@B32] Given the protective effects of CMV IgG against symptomatic CMV infection, further studies will be necessary to determine whether the administration of CMV-specific hyperimmune globulin to ELBWIs could prevent postnatal CMV infection acquired via breast milk and/or treat already established CMV disease, especially in ELBWIs of ≤24 weeks\' gestation.[@B39]

A few data exist on the long-term outcome of postnatal CMV infection acquired through breast milk in ELBWIs. In the present study, the majority of CMV infected ELBWIs were symptomatic and associated with adverse outcomes such as ≥moderate BPD. Nevertheless, the neurodevelopmental outcome and growth status of the CMV infection group were not significantly different compared to the control group at a CA of 2 years. Moreover, no hearing loss was observed in the postnatal CMV infection group. Overall, these results suggest that CMV infection acquired postnatally via breast milk in ELBWIs does not seem to be associated with long-term sequelae such as impaired development or hearing loss.[@B40]

In *in vitro* studies, freezing breast milk at -20℃ overnight, for more than 72 hours and 7 days reduced the CMV titer by 90%, 99%, and 100%, respectively.[@B10][@B11] Moreover, freeze-thawing preserved the nutritional and immunologic components of the breast milk.[@B15] However, although the transmission rate in the *in vivo* studies using freeze-thawed breast milk was significantly reduced to 6-22%[@B33][@B41][@B42][@B43] compared to 38-65% in studies with native untreated breast milk,[@B25][@B37][@B44] freezing could not completely inactivate the infectivity of the breast milk. In the present study, although the majority of infants did not acquire CMV infection, 8% of ELBWIs fed freeze-thawed mother\'s own breast milk stored at -20℃ for more than 3 days still acquired postnatal CMV infection. Overall, these findings suggest that despite its preservation of the nutritional and immunological benefits of breast milk, freezing breast milk at -20℃ for more than 3 days reduces but does not completely prevent CMV transmission through breast milk. Our finding of no postnatal acquisition of CMV when fed conventionally pasteurized breast milk at 63℃ for 30 min indicates that pasteurization could completely inactivate CMV and eradicate CMV transmission through breast milk even in ELBWIs of seropositive mothers.[@B45] Moreover, no significant differences in the outcomes between the period I and II indicates that pasteurization did not significantly reduce the immunological and clinical benefits of breast milk. However, concerns exist regarding the nutritional and immunological quality of breast milk after Holder pasteurization.[@B45] Therefore, further studies will be necessary to determine whether other measures such as short term pasteurization at 72℃ for 10 sec could effectively inactivate CMV without destroying the nutritional and immunological components of breast milk.[@B46]

Although pasteurization was shown to eradicate the postnatal acquisition of CMV infection via breast milk in this study, the duration of pasteurization necessary for ELBWIs born to seropositive mothers to prevent the transmission of CMV through breast milk is not yet known. The viral reactivation and shedding into breast milk might begin in the first week, reach a peak at 4-8 weeks, and rapidly decline from 9-12 postnatal weeks.[@B12] These findings suggest that feeding of colostrum might not be quite infectious regardless of freeze-thawing or pasteurization, and our finding of first detection of viruria at an average of 54 postnatal days coincides with the period of maximum viral shedding into breast milk. Taken together, these findings suggest that pasteurization starting from second week after birth for at least the first 8 postnatal weeks to the extremely preterm infants at the limit of viability will be necessary to effectively prevent CMV transmission through breast milk.

In summary, postnatally acquired CMV infection via breast milk was associated with serious symptoms and increased incidence of BPD, especially in ELBWIs with lower GA, and conventional pasteurization but not freeze-thawing of breast milk completely prevented the transmission of CMV through breast milk.
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###### Incidence of Postnatal Cytomegalovirus Infection during Period I and II

![](ymj-56-998-i001)

                  CMV infection    CMV detected in stored BM in period I   
  --------------- ---------------- --------------------------------------- ------------
  Total, n (%)    27/323 (8)       0/62 (0)^\*^                            11/17 (65)
  WMF             0/22 (0)         0/6 (0)                                 
  0%\<BMF≤60%     3/70 (4)         0/15 (0)                                1/3 (33)
  60%\<BMF≤100%   24/231 (10)^†^   0/41 (0)^†^                             10/14 (71)

CMV, cytomegalovirus; WMF, whole milk feeding; BMF, breast milk feeding.

^\*^*p* value\<0.05 compared to period I.

^†^*p* value\<0.05 compared to (0%\<BMF≤60%).

###### Clinical Characteristics of the Control and Cytomegalovirus Infection Group during Period I and II

![](ymj-56-998-i002)

                                       Period I (n=323)   Period II (n=62)   
  ------------------------------------ ------------------ ------------------ -----------------
  Gestational age (wk)                 26^+0^±2^+0^       24^+6^±1^+4\*^     25^+3^±1^+1^
  (Range)                              (21^+5^-34^+4^)    (23^+2^-30^+1^)    (23^+2^-30^+1^)
  Birth weight (gram)                  755±156            711±162            685±166^\*^
  (Range)                              (370-990)          (380-990)          (320-990)
  Apgar score at 1 min                 4.9±1.6            4.5±1.5            4.2±1.3^\*^
  Apgar score at 5 mins                7.3±1.4            6.9±1.5            6.6±1.5^\*^
  Male, n (%)                          139 (47)           15 (57)            30 (48)
  SGA, n (%)                           65 (22)            2 (7)              24 (39)^†^
  Cesarean section, n (%)              237 (80)           22 (81)            56 (90)
  PROM (≥24 hrs), n (%)                80 (27)            11 (41)            13 (21)
  Multiple pregnancies, n (%)          110 (37)           7 (25)             22 (39)
  Pathologic chorioamnionitis, n (%)   150 (51)           18 (67)            35 (56)
  PIH, n (%)                           59 (20)            2 (7)              4 (6)
  Gestational DM, n (%)                53 (18)            2 (7)              1 (2)
  Maternal steroid, n (%)              213 (72)           21 (78)            53 (85)
  Transfusion, n (%)                   276 (90)           25 (93)            59 (95)
  Frequency of transfusion             2.5±2.0            2.7±2.7            2.4±2.8

CMV, cytomegalovirus; SGA, small for gestational age; PROM, premature rupture of membrane; PIH, pregnancy induced hypertension; DM, diabetes mellitus. Data are expressed as mean±SD.

^\*^*p* value\<0.05 compared to control in period I.

^†^*p* value\<0.05 compared to CMV in period I.

###### Adverse Outcomes of the Control and CMV Infection Group during Period I and II

![](ymj-56-998-i003)

                                  Period I (n=323)   Period II (n=62)   
  ------------------------------- ------------------ ------------------ ----------
  Mortality, n (%)                33 (11)            3 (11)             10 (16)
  BPD (≥moderate), n (%)          121 (41)           23 (85)^\*^        23 (37)
  Ventilator care (days)          29±33              44±38^\*^          33±21
  CPAP care (day)                 30±26              36±28              27±19
  Oxygen therapy (days)           12±23              26±29              3±10^\*^
  ROP (laser op.), n (%)          80 (27)            11 (41)            14 (19)
  Sepsis (≥postnatal 1 month)     11 (4)             1 (4)              3 (5)
  NEC (≥stage II), n (%)          44 (15)            5 (19)             12 (19)
  IVH (≥grade III), n (%)         41 (14)            3 (11)             4 (6)
  Cystic PVL, n (%)               24 (8)             2 (7)              3 (5)
  Hospitalization (days)          103±53             124±66             102±45
  Full enteral feeding (days)     49±31              57±50              45±23
  Body weight at CA 36 wks (gm)   1758±398           1670±580           1714±309

CMV, cytomegalovirus; BPD, bronchopulmonary dysplasia; CPAP, continuous positive airway pressure; ROP, retinopathy of prematurity; NEC, necrotizing enterocolitis; IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia; CA, corrected age.

Data are expressed as mean±SD.

^\*^*p* value\<0.05 compared to control in period I.

###### Outcome at Corrected Age of 24 Months in the Control and Cytomegalovirus Infection Group

![](ymj-56-998-i004)

                            Control group (n=155)   CMV group (n=21)
  ------------------------- ----------------------- ------------------
  Cerebral palsy, n (%)     9 (6)                   1 (5)
   Group 1, n               6                       1
   Group 2, n               3                       0
   Group 3, n               0                       0
  Blindness, n (%)          0 (0)                   0 (0)
  Hearing loss, n (%)       1 (1)                   0 (0)
  BSID-II, n                92                      18
   MDI                      85±10                   85±31
    \<70, n (%)             12 (13)                 2 (11)
    70-84, n (%)            36 (39)                 4 (22)
    ≥85, n (%)              44 (48)                 12 (67)
   PDI                      84±16                   83±31
    \<70, n (%)             12 (13)                 2 (11)
    70-84, n (%)            24 (26)                 3 (17)
    ≥85, n (%)              56 (61)                 13 (72)
  Weight (kg)               10.4±1.4                10.9±1.3
  Height (cm)               83.5±3.8                85.2±3.6
  Head circumference (cm)   46.3±2.2                46.4±1.3
  Catch up growth, n (%)    66 (42)                 10 (47)

CMV, cytomegalovirus; BSID-II, Bayley Scales of Infant Development II; MDI, mental developmental index; PDI, psychomotor developmental index.

Data are expressed as mean±SD.

###### Adjusted Odds Ratios of Risk Factors for Developing CMV Infection
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                                *p* value   Odds ratio   95% CI
  ----------------------------- ----------- ------------ ------------
  Gestational age (/wk)         0.043       1.36         1.07-1.72
  Breast milk feeding (\>60%)   0.048       3.40         1.01-11.72
  Transfusion                   0.823       1.27         0.14-11.02
  PROM (≥24 hrs)                0.287       1.60         0.67-3.85

CMV, cytomegalovirus; PROM, premature rupture of membrane; CI, confidence interval.

###### Adjusted Odds Ratios for Adverse Outcomes of CMV Infection

![](ymj-56-998-i006)

                    *p* value   Odds ratio   95% CI
  ----------------- ----------- ------------ ------------
  BPD (≥moderate)   0.000       6.36         2.18-18.54
  NEC (≥Gr. II)     0.801       0.862        0.27-2.72
  ROP (laser op.)   0.245       1.693        0.69-4.11
  IVH (≥Gr. III)    0.348       1.84         0.51-6.673
  Cystic PVL        0.299       2.23         0.49-10.15

BPD, bronchopulmonary dysplasia; NEC, necrotizing enterocolitis; ROP, retinopathy of prematurity; IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia; Gr., grade; CMV, cytomegalovirus; CI, confidence interval.
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